RecruitingPhase 3NCT07011732
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Sponsor: Bristol-Myers Squibb
Foxborough, MA · Newton, MA · South Dartmouth, MA · +38 more sites